<DOC>
	<DOC>NCT03038880</DOC>
	<brief_summary>This is a Phase II, multicenter, randomized, active comparator-controlled, 52-week study to investigate the efficacy, safety and pharmacokinetics of RO6867461 (RG7716) administered with extended dosing regimens in treatment-naive participants with nAMD. Only one eye will be chosen as the study eye.</brief_summary>
	<brief_title>Study to Evaluate RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Neovascularization, Pathologic</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Inclusion Criteria Treatmentnaive CNV secondary to AMD Subfoveal or juxtafoveal CNV with a subfoveal component related to the CNV activity Active CNV BCVA letter score of 73 to 24 letters (inclusive) CNV due to causes other than AMD Retinal pigment epithelial tear involving the macula On fundus fluorescein angiography (FFA) subretinal hemorrhage, fibrosis or atrophy of &gt;50% of the total lesion area and/or that involves the fovea Cataract surgery within 3 months of baseline assessments Uncontrolled blood pressure</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>